TY - JOUR
T1 - An immunohistochemical analysis-based decision tree model for estimating the risk of lymphatic metastasis in pN0 squamous cell carcinomas of the lung
AU - Liu, Yu
AU - Lin, Dongmei
AU - Xiao, Ting
AU - Ma, Ying
AU - Hu, Zhi
AU - Zheng, Hongwei
AU - Zheng, Shan
AU - Liu, Yan
AU - Li, Min
AU - Li, Lin
AU - Cao, Yan
AU - Guo, Suping
AU - Han, Naijun
AU - Di, Xuebing
AU - Zhang, Kaitai
AU - Cheng, Shujun
AU - Gao, Yanning
PY - 2011/11
Y1 - 2011/11
N2 - Aims: Lung cancer patients within the pN0 category have a significantly different outcome. The aim of this study was to develop a mathematical model to assist in predicting the prognosis of pN0 lung squamous cell carcinoma (SCC). Methods and results: Twenty-three proteins were examined by immunohistochemical (IHC) analysis on primary tumour tissues from 319 lung SCC patients. In a training group, using IHC data, a recursive partitioning decision tree (RP-DT) was used to build a model for estimating the risk for lymphatic metastasis. This model was then validated in a test cohort. Of 23 proteins, 8 (matrix metallopeptidase 1, metalloproteinase inhibitor 1, Ras GTPase-activating-like protein IQGAP1, targeting protein for Xklp2, urokinase-type plasminogen activator, cathepsin D, fascin, polymeric immunoglobulin receptor/secretory component) were selected, and generated a tree model in a training group of 255 patients to classify them as at high or low risk of lymphatic invasion, with accuracy of 78.0% (compared to histopathological diagnosis), sensitivity of 83.0% and specificity of 70.3%. When the tree model was applied to the test group, the accuracy, sensitivity and specificity were 76.6%, 76.0% and 76.9%, respectively. The performance of this mathematical model was substantiated further in 34 'problematic' stage I/pN0 patients by survival analysis. Conclusions: The RP-DT model, constructed with eight protein markers for estimating lymphatic metastasis risk in pN0 lung SCC, is clinically feasible and practical, using IHC data from the primary tumour.
AB - Aims: Lung cancer patients within the pN0 category have a significantly different outcome. The aim of this study was to develop a mathematical model to assist in predicting the prognosis of pN0 lung squamous cell carcinoma (SCC). Methods and results: Twenty-three proteins were examined by immunohistochemical (IHC) analysis on primary tumour tissues from 319 lung SCC patients. In a training group, using IHC data, a recursive partitioning decision tree (RP-DT) was used to build a model for estimating the risk for lymphatic metastasis. This model was then validated in a test cohort. Of 23 proteins, 8 (matrix metallopeptidase 1, metalloproteinase inhibitor 1, Ras GTPase-activating-like protein IQGAP1, targeting protein for Xklp2, urokinase-type plasminogen activator, cathepsin D, fascin, polymeric immunoglobulin receptor/secretory component) were selected, and generated a tree model in a training group of 255 patients to classify them as at high or low risk of lymphatic invasion, with accuracy of 78.0% (compared to histopathological diagnosis), sensitivity of 83.0% and specificity of 70.3%. When the tree model was applied to the test group, the accuracy, sensitivity and specificity were 76.6%, 76.0% and 76.9%, respectively. The performance of this mathematical model was substantiated further in 34 'problematic' stage I/pN0 patients by survival analysis. Conclusions: The RP-DT model, constructed with eight protein markers for estimating lymphatic metastasis risk in pN0 lung SCC, is clinically feasible and practical, using IHC data from the primary tumour.
KW - Decision tree
KW - Immunohistochemical analysis
KW - Lymphatic metastasis
KW - Prognosis
KW - Squamous cell carcinomas of the lung
UR - http://www.scopus.com/inward/record.url?scp=81555200677&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=81555200677&partnerID=8YFLogxK
U2 - 10.1111/j.1365-2559.2011.04013.x
DO - 10.1111/j.1365-2559.2011.04013.x
M3 - Article
C2 - 22092400
AN - SCOPUS:81555200677
SN - 0309-0167
VL - 59
SP - 882
EP - 891
JO - Histopathology
JF - Histopathology
IS - 5
ER -